Real-world Use and Prognosis of Beta Blocker in Patients With Acute Coronary Syndrome in the Central China

Launched by HENAN INSTITUTE OF CARDIOVASCULAR EPIDEMIOLOGY · Apr 12, 2017

Keywords

ClinConnect Summary

1. Henan institute of cardiology epidemiology is responsible for design, data quality control and statistical analysis.
2. Data were collected using a uniformed Case Report Form(CRF) by trained staff at each hospital.
3. Sample size estimation: Based on retrospective observational cohort of ACS patients, 1-year mortality in beta-blocker recipients and non-beta-blocker recipients were 2.5% and 5.6%, respectively. To achieve a precision of 5% with an α of 0.05, the loss ratio of following-up is 15%.The investigators would need a sample of 3000.
4. Statistical analysis plan: the investigators ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age≥18 years.
• • 2. Patients with clinical evidence of acute coronary syndrome, including ST segment elevation myocardial infarction (STEMI), non ST segment elevation myocardial infarction (NSTEMI) and unstable angina.
• • 3. Informed consent signed by patients or legal guardians.
• Exclusion Criteria:
• • Expected survival \<12 months